Multipotent mesenchymal stromal cells and the innate immune system

Nature Reviews Immunology

Volumn 12, Issue 5, 2012, Pages 383-396

  Le Blanc, Katarina ^a   Mougiakakos, Dimitrios ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NESTIN; PATTERN RECOGNITION RECEPTOR; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIMICROBIAL ACTIVITY; AUTOIMMUNITY; BONE MARROW; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUSION; CELL MATURATION; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; CIRCADIAN RHYTHM; CLINICAL EFFECTIVENESS; COMPLEMENT SYSTEM; CORD BLOOD STEM CELL TRANSPLANTATION; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; FIBROBLAST; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; IN VITRO STUDY; INFLAMMATION; INNATE IMMUNITY; LICENSING; LUNG INJURY; MACROPHAGE; MAST CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOLECULAR INTERACTION; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OSTEOBLAST; OXIDATIVE STRESS; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RESPIRATORY BURST; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ULCERATIVE COLITIS; UMBILICAL CORD; VIRUS INFECTION; WOUND HEALING;

BONE MARROW CELLS; HUMANS; IMMUNITY, INNATE; MESENCHYMAL STEM CELLS; MESENCHYMAL STROMAL CELLS;

EID: 84860238652     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3209     Document Type: Review

References (140)

1. Luria, E. A., Panasyuk, A. F. & Friedenstein, A. Y. Fibroblast colony formation from monolayer cultures of blood cells. Transfusion 11, 345-349 (1971).
2. Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nature Rev. Immunol. 8, 726-736 (2008).
3. Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999). (Pubitemid 29282067)
4. Tremain, N. et al. MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages. Stem Cells 19, 408-418 (2001). (Pubitemid 32900083)
5. Sacchetti, B. et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324-336 (2007). (Pubitemid 47592917)
6. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006). (Pubitemid 44269669)
7. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-1586 (2008). (Pubitemid 351626841)
8. Duijvestein, M. et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59, 1662-1669 (2010).
9. Ciccocioppo, R. et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60, 788-798 (2011).
10. Connick, P. et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 11, 150-156 (2012).
11. Bachmann, M. F. & Kopf, M. On the role of the innate immunity in autoimmune disease. J. Exp. Med. 193, F47-F50 (2001). (Pubitemid 32565961)
12. Chow, A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 208, 261-271 (2011).
13. Shi, C. et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating Toll-like receptor ligands. Immunity 34, 590-601 (2011).
14. Schofield, R. The stem cell system. Biomed. Pharmacother. 37, 375-380 (1983). (Pubitemid 14194496)
15. Wilson, A. & Trumpp, A. Bone-marrow haematopoietic-stem-cell niches. Nature Rev. Immunol. 6, 93-106 (2006). (Pubitemid 43361585)
16. Mendes, S. C., Robin, C. & Dzierzak, E. Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. Development 132, 1127-1136 (2005). (Pubitemid 40484945)
17. Friedenstein, A. J., Latzinik, N. W., Grosheva, A. G. & Gorskaya, U. F. Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. Exp. Hematol. 10, 217-227 (1982). (Pubitemid 12178909)
18. Calvi, L. M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003). (Pubitemid 37351468)
19. Naveiras, O. et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460, 259-263 (2009).
20. Mendez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829-834 (2010).
21. Omatsu, Y. et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 33, 387-399 (2010).
22. Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977-988 (2006). (Pubitemid 44894948)
23. Mendez-Ferrer, S., Lucas, D., Battista, M. & Frenette, P. S. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452, 442-447 (2008). (Pubitemid 351450836)
24. Winkler, I. G. et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815-4828 (2010).
25. Liotta, F. et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26, 279-289 (2008).
26. Bernardo, M. E., Cometa, A. M. & Locatelli, F. Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation? Bone Marrow Transplant. 47, 323-329 (2011).
27. Koc, O. N. et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18, 307-316 (2000). (Pubitemid 30056419)
28. Cilloni, D. et al. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 96, 3637-3643 (2000).
29. Rieger, K. et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp. Hematol. 33, 605-611 (2005). (Pubitemid 40592178)
30. Phinney, D. G. & Prockop, D. J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 25, 2896-2902 (2007). (Pubitemid 350127874)
31. Meirelles Lda, S., Fontes, A. M., Covas, D. T. & Caplan, A. I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 20, 419-427 (2009).
32. Ganz, T. Epithelia: not just physical barriers. Proc. Natl Acad. Sci. USA 99, 3357-3358 (2002). (Pubitemid 34252111)
33. Signore, M. et al. Identity and ranking of colonic mesenchymal stromal cells. J. Cell. Physiol. 14 Dec 2011 (doi:10.1002/jcp.24027).
34. Diaz-Flores, L. et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 24, 909-969 (2009).
35. Brittan, M. & Wright, N. A. Stem cell in gastrointestinal structure and neoplastic development. Gut 53, 899-910 (2004). (Pubitemid 38662143)
36. Brown, S. L. et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest. 117, 258-269 (2007). (Pubitemid 46048471)
37. Goessling, W. et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136-1147 (2009).
38. Ferrand, J. et al. Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS ONE 6, e19569 (2011).
39. Sasaki, M. et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 180, 2581-2587 (2008).
40. Prockop, D. J. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin. Pharmacol. Ther. 82, 241-243 (2007). (Pubitemid 47258475)
41. Lee, J. W., Fang, X., Gupta, N., Serikov, V. & Matthay, M. A. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc. Natl Acad. Sci. USA 106, 16357-16362 (2009).
42. Semont, A. et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 17, 952-961 (2010).
43. Jakob, M. et al. Human nasal mucosa contains tissue-resident immunologically responsive mesenchymal stromal cells. Stem Cells Dev. 19, 635-644 (2010).
44. Lanzoni, G. et al. Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. Cytotherapy 11, 1020-1031 (2009).
45. Powell, D. W., Pinchuk, I. V., Saada, J. I., Chen, X. & Mifflin, R. C. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 73, 213-237 (2011).
46. Chen, L., Tredget, E. E., Wu, P. Y. & Wu, Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 3, e1886 (2008).
47. Nemeth, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Med. 15, 42-49 (2009).
48. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nature Rev. Immunol. 8, 958-969 (2008).
49. Maggini, J. et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS ONE 5, e9252 (2010).
50. Karp, J. M. & Leng Teo, G. S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4, 206-216 (2009).
51. Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54-63 (2009).
52. Kim, J. & Hematti, P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 37, 1445-1453 (2009).
53. Francois, M., Romieu-Mourez, R., Li, M. & Galipeau, J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol. Ther. 20, 187-195 (2011).
54. Croitoru-Lamoury, J. et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS ONE 6, e14698 (2011).
55. Mougiakakos, D. et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117, 4826-4835 (2011).
56. Gupta, N. et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J. Immunol. 179, 1855-1863 (2007).
57. Choi, H., Lee, R. H., Bazhanov, N., Oh, J. Y. & Prockop, D. J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood 118, 330-338 (2011).
58. Ortiz, L. A. et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl Acad. Sci. USA 104, 11002-11007 (2007). (Pubitemid 47175216)
59. Groh, M. E., Maitra, B., Szekely, E. & Koc, O. N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33, 928-934 (2005). (Pubitemid 40982660)
60. Cassatella, M. A. et al. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 29, 1001-1011 (2011).
61. Raffaghello, L. et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26, 151-162 (2008).
62. Tate, M. D. et al. Neutrophils ameliorate lung injury and the development of severe disease during influenza infection. J. Immunol. 183, 7441-7450 (2009).
63. Brandau, S. et al. Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge. J. Leukoc. Biol. 88, 1005-1015 (2010).
64. Romieu-Mourez, R. et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J. Immunol. 182, 7963-7973 (2009).
65. Bischoff, S. C. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nature Rev. Immunol. 7, 93-104 (2007). (Pubitemid 46174857)
66. Brown, J. M., Nemeth, K., Kushnir-Sukhov, N. M., Metcalfe, D. D. & Mezey, E. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin. Exp. Allergy 41, 526-534 (2011).
67. Su, W. R., Zhang, Q. Z., Shi, S. H., Nguyen, A. L. & Le, A. D. Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prostaglandin E2-dependent mechanisms. Stem Cells 29, 1849-1860 (2011).
68. Kavanagh, H. & Mahon, B. P. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 66, 523-531 (2011).
69. Bouffi, C., Bony, C., Courties, G., Jorgensen, C. & Noel, D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS ONE 5, e14247 (2010).
70. Rasmusson, I., Ringden, O., Sundberg, B. & Le Blanc, K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76, 1208-1213 (2003). (Pubitemid 37339646)
71. Poggi, A. et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J. Immunol. 175, 6352-6360 (2005). (Pubitemid 41598875)
72. Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C. & Moretta, L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484-1490 (2006). (Pubitemid 43242385)
73. Patel, S. A. et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-β. J. Immunol. 184, 5885-5894 (2010).
74. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N. & Papamichail, M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24, 74-85 (2006).
75. Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005). (Pubitemid 40223708)
76. Spaggiari, G. M. et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood 111, 1327-1333 (2008). (Pubitemid 351213419)
77. Selmani, Z. et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26, 212-222 (2008).
78. Gotherstrom, C. et al. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy 13, 269-278 (2011).
79. Krampera, M. et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24, 386-398 (2006). (Pubitemid 44464808)
80. Stockinger, B., Veldhoen, M. & Martin, B. Th17 T cells: linking innate and adaptive immunity. Semin. Immunol. 19, 353-361 (2007). (Pubitemid 351274048)
81. Geddes, K. et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nature Med. 17, 837-844 (2011).
82. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485-517 (2009).
83. Huang, W., La Russa, V., Alzoubi, A. & Schwarzenberger, P. Interleukin-17A: a T-cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells 24, 1512-1518 (2006). (Pubitemid 44464668)
84. Bai, L. et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57, 1192-1203 (2009).
85. Rafei, M. et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182, 5994-6002 (2009).
86. Ghannam, S., Pene, J., Torcy-Moquet, G., Jorgensen, C. & Yssel, H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185, 302-312 (2010).
87. Duffy, M. M. et al. Mesenchymal stem cell inhibition of T-helper 17 differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur. J. Immunol. 41, 2840-2851 (2011).
88. Tso, G. H., Law, H. K., Tu, W., Chan, G. C. & Lau, Y. L. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cells 28, 939-954 (2010).
89. Tatara, R. et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13, 686-694 (2011).
90. Carrion, F., Nova, E., Luz, P., Apablaza, F. & Figueroa, F. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol. Lett. 135, 10-16 (2011).
91. Darlington, P. J. et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann. Neurol. 68, 540-545 (2010).
92. Markiewski, M. M. & Lambris, J. D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 171, 715-727 (2007). (Pubitemid 47440971)
93. Schraufstatter, I. U., Discipio, R. G., Zhao, M. & Khaldoyanidi, S. K. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J. Immunol. 182, 3827-3836 (2009).
94. Mougiakakos, D., Johansson, C. C., Jitschin, R., Bottcher, M. & Kiessling, R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood 117, 857-861 (2011).
95. Schraufstatter, I. U., Discipio, R. G. & Khaldoyanidi, S. Mesenchymal stem cells and their microenvironment. Front. Biosci. 17, 2271-2288 (2011).
96. Toma, C., Wagner, W. R., Bowry, S., Schwartz, A. & Villanueva, F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ. Res. 104, 398-402 (2009).
97. Ratajczak, J. et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 103, 2071-2078 (2004). (Pubitemid 38326222)
98. Moll, G. et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS ONE 6, e21703 (2011).
99. Komoda, H. et al. Reduction of N-glycolylneuraminic acid xenoantigen on human adipose tissue-derived stromal cells/mesenchymal stem cells leads to safer and more useful cell sources for various stem cell therapies. Tissue Eng. Part A 16, 1143-1155 (2010).
100. Ignatius, A. et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. J. Cell. Biochem. 112, 2594-2605 (2011).
101. Tu, Z., Li, Q., Bu, H. & Lin, F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 19, 1803-1809 (2010).
102. Nilsson, B., Ekdahl, K. N. & Korsgren, O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr. Opin. Organ Transplant. 16, 620-626 (2011).
103. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol. 11, 373-384 (2010).
104. Lombardo, E. et al. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng. Part A 15, 1579-1589 (2009).
105. Opitz, C. A. et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-β and protein kinase R. Stem Cells 27, 909-919 (2009).
106. Tomchuck, S. L. et al. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26, 99-107 (2008).
107. Pevsner-Fischer, M. et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109, 1422-1432 (2007). (Pubitemid 46239573)
108. Tomic, S. et al. Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by Toll-like receptor agonists. Stem Cells Dev. 20, 695-708 (2011).
109. Van den Berk, L. C. et al. Toll-like receptor triggering in cord blood mesenchymal stem cells. J. Cell. Mol. Med. 13, 3415-3426 (2009).
110. Hwa Cho, H., Bae, Y. C. & Jung, J. S. Role of Toll-like receptors on human adipose-derived stromal cells. Stem Cells 24, 2744-2752 (2006).
111. Raicevic, G. et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum. Immunol. 71, 235-244 (2010).
112. Mo, I. F. et al. Prolonged exposure to bacterial toxins downregulated expression of Toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors. BMC Cell Biol. 9, 52 (2008).
113. Yu, S., Cho, H. H., Joo, H. J., Bae, Y. C. & Jung, J. S. Role of MyD88 in TLR agonist-induced functional alterations of human adipose tissue-derived mesenchymal stem cells. Mol. Cell. Biochem. 317, 143-150 (2008).
114. Sioud, M., Mobergslien, A., Boudabous, A. & Floisand, Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand. J. Immunol. 71, 267-274 (2010).
115. Kim, H. S. et al. Implication of NOD1 and NOD2 for the differentiation of multipotent mesenchymal stem cells derived from human umbilical cord blood. PLoS ONE 5, e15369 (2010).
116. Wang, Z. J. et al. Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via Toll-like receptor(TLR)-4 and PI3K/Akt. Cell Biol. Int. 33, 665-674 (2009).
117. Nurmenniemi, S. et al. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp. Cell Res. 316, 2676-2682 (2010).
118. DelaRosa, O. & Lombardo, E. Modulation of adult mesenchymal stem cells activity by Toll-like receptors: implications on therapeutic potential. Mediators Inflamm. 2010, 865601 (2010).
119. Marriott, I. Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression. Immunol. Res. 30, 291-308 (2004). (Pubitemid 39546231)
120. Detante, O. et al. Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplant. 18, 1369-1379 (2009).
121. Waterman, R. S., Tomchuck, S. L., Henkle, S. L. & Betancourt, A. M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5, e10088 (2010).
122. Ferrari, D. et al. Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp. Hematol. 39, 360-374 (2011).
123. Gonzalez-Rey, E. et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58, 929-939 (2009).
124. Cavassani, K. A. et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J. Exp. Med. 205, 2609-2621 (2008).
125. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150 (2008). (Pubitemid 351181031)
126. English, K., Barry, F. P., Field-Corbett, C. P. & Mahon, B. P. IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 110, 91-100 (2007). (Pubitemid 46830943)
127. Polchert, D. et al. IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38, 1745-1755 (2008).
128. Chan, J. L. et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 107, 4817-4824 (2006). (Pubitemid 43882633)
129. Abreu, M. T., Fukata, M. & Arditi, M. TLR signaling in the gut in health and disease. J. Immunol. 174, 4453-4460 (2005).
130. Taylor, P. A. et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 112, 3508-3516 (2008).
131. Meisel, R. et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 25, 648-654 (2011).
132. Krasnodembskaya, A. et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 28, 2229-2238 (2010).
133. Mei, S. H. et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am. J. Respir. Crit. Care Med. 182, 1047-1057 (2010).
134. Karlsson, H. et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 112, 532-541 (2008).
135. Kang, H. S. et al. A paradoxical role for IFN-γ in the immune properties of mesenchymal stem cells during viral challenge. Exp. Hematol. 33, 796-803 (2005). (Pubitemid 40826593)
136. Smirnov, S. V. et al. Bone-marrow-derived mesenchymal stem cells as a target for cytomegalovirus infection: implications for hematopoiesis, self-renewal and differentiation potential. Virology 360, 6-16 (2007).
137. Sundin, M. et al. Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: implications for transplantation. Biol. Blood Marrow Transplant. 14, 1172-1179 (2008).
138. Morandi, F. et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 26, 1275-1287 (2008).
139. Prigione, I. et al. Reciprocal interactions between human mesenchymal stem cells and γδ T cells or invariant natural killer T cells. Stem Cells 27, 693-702 (2009).
140. Nemeth, K. et al. Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl Acad. Sci. USA 107, 5652-5657 (2010).